Es­pe­ri­on stock halved af­ter Dai­ichi dis­cord over $440M heart pill mile­stones

Es­pe­ri­on’s CLEAR Out­comes tri­al does not have a clear out­come re­gard­ing part­ner Dai­ichi Sankyo pony­ing up the big biobucks.

Es­pe­ri­on’s heart pill, which has strug­gled to gain trac­tion, was due for up to $440 mil­lion in mile­stones from Dai­ichi fol­low­ing a da­ta read­out ear­li­er this month aim­ing to ex­pand the EU and US la­bels.

But the Michi­gan biotech’s part­ner ap­pears to dis­agree on which da­ta would trig­ger the pay­ments. Es­pe­ri­on out­lined the mis­matched views in an SEC fil­ing Wednes­day af­ter­noon, and in­vestors sent the com­pa­ny’s stock $ES­PR on a rapid 54% de­cline in af­ter-hours trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER